Comeo has been officially certified under the EU MDR regulation by BSI for its flagship solution, ComeoCare. This certification validates our commitment to the highest standards of safety, performance, and compliance in digital healthcare. With the MDR approval, Comeo is poised to expand beyond Belgium and Switzerland into new European markets.

Our partner BELIEVETec was recently recognized as Gold Sponsor of the Pan Arab Thalassemia & Sickle Cell Conference. These diseases require complex, protocol-based treatments — exactly what ComeoCare supports through smart, connected care across departments. Proud to empower better outcomes together.

B. Braun showcased their OnkoLogisch project at the ADKA Congress in Berlin including ComeoCare, highlighting how our solution supports safe, closed-loop oncology workflows. It was great to connect with passionate professionals, the Kiro Grifols team, and see our solution featured in guided tours with real-world insights.

ComeoCare was presented by our local partner BelieveTec at the 2nd Pharmaceutical Oncology Conference in Kuwait. The event brought together oncology professionals from across the Gulf region as well as international speakers, offering a great opportunity to showcase how ComeoCare supports safer cancer care through flexible, end-to-end digital workflows for pharmacists, physicians, and nurses.

Comeo is more than just a name — it’s a brand that embodies our commitment to enhancing patient care.

Join us January 24-25 in Blankenberge to discover the groundbreaking integration of ComeoCare with B.Braun's Oncosafety at our joint stand. Experience a fully closed-loop solution ensuring seamless automation from prescription to IV pump programming, enhancing safety and efficiency in oncology care.

We had a great experience at the GSASA conference in Basel, connecting with Swiss hospital pharmacists and showcasing our solutions. As one of the few software vendors, we were inspired by the interest in digital innovation and meaningful discussions with industry leaders. Thank you to all who visited us—we’re excited about what’s next!